SCHEMBL310207

SCHEMBL310207

CCOc1cc(N2CCC(N3CCN(CCS(C)(=O)=O)CC3)CC2)ccc1N

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGFR P00533 5/20 0.41
LGMN Q99538 1/20 0.39
INSR P06213 5/20 0.39
IGF1R P08069 4/20 0.39
ALK Q9UM73 3/20 0.39
ALDH1A1 P00352 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
L3MBTL3 Q96JM7 3/20 0.38
L3MBTL1 Q9Y468 3/20 0.38
TP53BP1 Q12888 2/20 0.38
MAPT P10636 1/20 0.37
KCNH2 Q12809 1/20 0.37
KMT2A Q03164 2/20 0.37
MBTD1 Q05BQ5 1/20 0.37
BMPR1B O00238 1/20 0.37
PLK4 O00444 1/20 0.37
GAK O14976 1/20 0.37
ERN1 O75460 1/20 0.37
STK10 O94804 1/20 0.37
ABL1 P00519 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL310840 0.96 ALDH1A1 (0.42) EGFRLGMNINSRIGF1RALK
SCHEMBL311234 0.90 EGFR (0.45) EGFRINSRIGF1RALKL3MBTL3
SCHEMBL310335 0.89 GAA (0.45) IGF1RALKALDH1A1SMN1; SMN2L3MBTL1
SCHEMBL10257009 0.88 ALDH1A1 (0.42) EGFRINSRIGF1RALKALDH1A1
SCHEMBL310764 0.86 ALDH1A1 (0.42) LGMNINSRIGF1RALKALDH1A1
SCHEMBL311522 0.86 RECQL (0.44) EGFRLGMNINSRIGF1RALK
SCHEMBL310977 0.85 EGFR (0.42) EGFRINSRIGF1RALKALDH1A1
SCHEMBL12917658 0.85 ALK (0.47) EGFRLGMNINSRIGF1RALK
SCHEMBL310377 0.84 ALDH1A1 (0.44) LGMNINSRIGF1RALKALDH1A1
SCHEMBL310642 0.82 ALDH1A1 (0.47) LGMNINSRIGF1RALKALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2162454-B1 IMIDAZOPYRIDINE KINASE INHIBITORS GLAXOSMITHKLINE LLC (US) 2013-01-02 EP disclosed
EP-2162454-B1 IMIDAZOPYRIDINE KINASE INHIBITORS GLAXOSMITHKLINE LLC (US) 2013-01-02 EP disclosed
US-8093239-B2 Imidazopyridine kinase inhibitors GLAXOSMITHKLINE LLC (US) 2012-01-10 US disclosed
US-8093239-B2 Imidazopyridine kinase inhibitors GLAXOSMITHKLINE LLC (US) 2012-01-10 US disclosed
US-8093239-B2 Imidazopyridine kinase inhibitors GLAXOSMITHKLINE LLC (US) 2012-01-10 US disclosed
US-20100216779-A1 Imidazopyridine Kinase Inhibitors GLAXOSMITHKLINE LLC 2010-08-26 US disclosed
US-20100216779-A1 Imidazopyridine Kinase Inhibitors GLAXOSMITHKLINE LLC 2010-08-26 US disclosed
US-20100216779-A1 Imidazopyridine Kinase Inhibitors GLAXOSMITHKLINE LLC 2010-08-26 US disclosed
EP-2162454-A1 IMIDAZOPYRIDINE KINASE INHIBITORS GlaxoSmithKline LLC (US) 2010-03-17 EP disclosed
WO-2008150799-A1 IMIDAZOPYRIDINE KINASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2008-12-11 WO disclosed
WO-2008150799-A1 IMIDAZOPYRIDINE KINASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2008-12-11 WO disclosed
US-20080300242-A1 Imidazopyridine Kinase Inhibitors GLAXOSMITHKLINE LLC 2008-12-04 US disclosed
US-20080300242-A1 Imidazopyridine Kinase Inhibitors GLAXOSMITHKLINE LLC 2008-12-04 US disclosed
US-20080300242-A1 Imidazopyridine Kinase Inhibitors GLAXOSMITHKLINE LLC 2008-12-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080300242-A1 Imidazopyridine Kinase Inhibitors ABL1, MAP3K19, MAP3K5 EGFR 491/4885LGMN 3434/4885INSR 814/4885
US-20100216779-A1 Imidazopyridine Kinase Inhibitors ABL1, MAP3K19, MAP3K5 EGFR 491/4885LGMN 3434/4885INSR 814/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.